A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms JULIET
- Sponsors Novartis
- 03 Apr 2018 Planned End Date changed from 1 Jan 2020 to 20 Feb 2023.
- 03 Apr 2018 Planned primary completion date changed from 1 Jan 2024 to 20 Feb 2023.
- 14 Mar 2018 Planned End Date changed from 1 Jan 2024 to 1 Jan 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History